Atenolol oral en el manejo del hemangioma infantil: serie de casos de 46 pacientes

Calderón-Castrat, Ximena; Velásquez, Felipe; Castro, R.; Ballona, Rosalía

doi:10.1016/j.ad.2019.03.015

Cited by 9 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These infants showed a low Sleep Efficiency on propranolol, which improved when they were switched to atenolol. While the number of atenolol-treated infants in this study was low, our findings are in keeping with previous reports suggesting that infants with sleep problems on propranolol might benefit from hydrophilic beta-blockers such as atenolol [ 27 , 48 ]. Larger-scale studies targeting specifically the small subgroup of infants whose sleep is affected by propranolol are required to understand why high susceptibility towards sleep disturbances under propranolol can in rare cases occur.…”

Section: Discussionsupporting

confidence: 91%

Sleep behavior of infants with infantile hemangioma treated with propranolol—a cohort study

et al. 2021

View full text Add to dashboard Cite

Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function. In this cohort study, we objectively investigate the sleep behavior of infants with infantile hemangiomas on propranolol compared to a healthy, untreated control group. Sleep of propranolol-treated infants and controls was investigated using ankle actigraphy and a 24-h diary for 7–10 days at ages 3 and 6 months. The main outcome measures were the Number of Nighttime Awakenings and Sleep Efficiency. The main secondary outcome measures included 24-hour Total Sleep, daytime sleep behavior, and parent-rated infant sleep quality and behavioral development based on the Brief Infant Sleep Questionnaire (BISQ) and the age-appropriate Ages-and-Stages Questionnaire (ASQ), respectively. Fifty-four term-born infants were included in each cohort. No group difference in any investigated parameter was seen at age 3 months. At age 6 months, the propranolol group exhibited a decrease in Sleep Efficiency and a trend towards an increased Number of Nighttime Awakenings compared to the control group. Treated infants at 6 months also had shorter daytime waking periods. 24-hour Total Sleep was unaffected by propranolol. No negative impact of propranolol on subjective sleep quality and behavioral development was noted.Conclusion: Propranolol exerts a measurable yet mild impact on objectively assessed infants’ sleep measures. Behavioral developmental scores were unaffected. Our results support propranolol as first-line therapy for complicated infantile hemangiomas. What is Known:• Sleep disorders are frequently reported in infants with infantile hemangiomas treated with propranolol and often lead to treatment discontinuation.• Investigations of the sleep pattern in this patient group using objective measures are lacking. What is New:• The sleep pattern of propranolol-treated infants is assessed using actigraphy and a 24-h sleep diary and compared to healthy, untreated controls.• Propranolol leads to a decreased sleep efficiency at night and an increased demand of daytime sleep, yet effects are mild overall.

show abstract

Section: Discussionsupporting

confidence: 91%

Sleep behavior of infants with infantile hemangioma treated with propranolol—a cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It is worth mentioning that no recurrence after the end of the treatment was observed, and a mean time of 16,4 days was required to close the wounds of ulcerated hemangiomas. The most common side effect was mild transient diarrhea affecting almost one-quarter of patients [45]. Another case report showed similar results concerning less-frequent sleep disturbances than during propranolol treatment [46].…”

Section: Atenololmentioning

confidence: 61%

Infantile Hemangiomas: An Update on Pathogenesis and Treatment

Kowalska

Dębek

Matuszczak

2021

JCM

View full text Add to dashboard Cite

Infantile hemangiomas are the most common benign vascular tumors in infancy. This review includes an update on the current knowledge on pathogenesis, a discussion on indications for treatment, and a review of the mechanisms underlying the different treatment methods. Although most infantile hemangiomas require only active observation because of their natural course, which results in involution, about 10% present with complications that require immediate treatment. The basic treatment includes systemic and topical options. In cases of insufficient response or rebound growth, other forms of treatment should be considered. In some cases, combined therapy might be initiated.

show abstract

“…Sin embargo, aunque poco frecuente, un subgrupo de pacientes experimenta efectos secundarios indeseables, lo que despierta el interés sobre otros betabloqueantes selectivos. (11)…”

Section: Discussionunclassified

Multiple congenital hemangioma in the scrotal area: case report

Jiménez¹,

Fernández

Auza-Santiváñez

2022

Salud, Ciencia y Tecnología

View full text Add to dashboard Cite

Los hemangiomas congénitos son tumores de tipo vascular, de los cuales se clasifican de rápida involución y no involutivos. Afectan principalmente a la población de raza caucásica, la distribución por sexo no es significativa. En la mayoría de los casos no se requiere tratamiento debido a la involución, sin embargo, cuando esto no es así el cuadro clínico de un hemangioma puede estar asociado a complicaciones como: ulceras, destrucción de los tejidos blandos, neoformaciones incluso con infección del tejido lesionado. El presente reporte de caso presenta un paciente de 7 meses de edad con hemangiomas congénitos múltiples de tipo no involutivos que llevaron a un proceso de ulceración con una posterior sobreinfección en la zona escrotal comprometiendo tejido blando. El tratamiento fue de tipo clínico y quirúrgico, se utilizó un betabloqueante selectivo, con un pronóstico favorable del paciente.

show abstract

Atenolol oral en el manejo del hemangioma infantil: serie de casos de 46 pacientes

Cited by 9 publications

References 9 publications

Sleep behavior of infants with infantile hemangioma treated with propranolol—a cohort study

Sleep behavior of infants with infantile hemangioma treated with propranolol—a cohort study

Infantile Hemangiomas: An Update on Pathogenesis and Treatment

Multiple congenital hemangioma in the scrotal area: case report

Contact Info

Product

Resources

About